Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Clinical trial NCT02719574 · COMPLETED

Trial details

NCT number: NCT02719574
Sponsor: Forma Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Acute Myelogenous Leukemia Myelodysplastic Syndrome

Start date: 2016-04-30
Primary completion: 2023-12-28
Enrollment: 336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.